Brief: Avenue Therapeutics Announces FDA Advisory Committee Meeting To Review IV Tramadol NDA Tentatively Scheduled For February 15, 2022
29/11/2021 13:06
Nov 29 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE
MEETING TO
REVIEW IV TRAMADOL NDA TENTATIVELY SCHEDULED FOR FEBRUARY 15,
2022
Source text for Eikon: ID:nGNX8MWz1y
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary